VIRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viracta Therapeutics's yield on cost for the quarter that ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Viracta Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Viracta Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Viracta Therapeutics is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Viracta Therapeutics (NAS:VIRX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Viracta Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel R. Chevallard | officer: Chief Executive Officer | C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Mark Rothera | director, officer: President and CEO | C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Darrel P. Cohen | officer: Chief Medical Officer | C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007 |
Lisa Rojkjaer | officer: Chief Medical Officer | C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007 |
Ivor Royston | director, officer: CEO & President | 4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010 |
Jane Chung | director | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Flavia Borellini | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Barry J. Simon | director | 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007 |
Stephen Rubino | director | C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007 |
Gur Roshwalb | director, 10 percent owner | C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael Huang | director | C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Thomas E Darcy | director | C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 11-13-2024
By GuruFocus Research • 03-07-2024
By GuruFocus Research • 03-07-2024
By GuruFocus Research • 03-07-2024
By Marketwired • 05-07-2024
By GuruFocus Research • 03-07-2024
By PRNewswire • 03-08-2024
By GuruFocus Research • 03-07-2024
By GuruFocus Research • 11-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.